HighTower Advisors LLC Sells 869 Shares of Eli Lilly and Company $LLY

HighTower Advisors LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 435,692 shares of the company’s stock after selling 869 shares during the period. HighTower Advisors LLC’s holdings in Eli Lilly and Company were worth $504,131,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of LLY. BlackRock Inc. boosted its position in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. State Street Corp increased its holdings in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after acquiring an additional 605,752 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after acquiring an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC raised its position in shares of Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after acquiring an additional 400,538 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on LLY shares. Leerink Partners boosted their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 21st. Citigroup raised their price objective on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a research report on Monday, November 9th. Royal Bank Of Canada boosted their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research report on Friday, October 30th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $1,650.00 target price on shares of Eli Lilly and Company in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,422.00.

Read Our Latest Report on LLY

Recent Eli Lilly and Company Headlines

Investors following LLY have been watching these headlines:

  • Positive Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding experimental treatments for rare blood cancers—essential thrombocythemia and myelofibrosis—and broadening its portfolio beyond obesity drugs. The medicines are still in development, so their commercial potential is not yet established. Read article
  • Positive Sentiment: Retatrutide beat Novo Nordisk’s Ozempic in a head-to-head trial, a result that could reinforce Lilly’s competitive position in the expanding GLP-1 market. One report estimates that market could reach $190 billion by 2035. Read article
  • Positive Sentiment: New ObesityWeek data covered Zepbound, Foundayo, EloraTZP, and retatrutide, with reported efficacy signals across weight loss and related conditions. The findings may support Lilly’s pipeline and future growth prospects. Read article

Eli Lilly and Company Stock Down 0.9%

Eli Lilly and Company stock opened at $1,431.12 on Tuesday. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a market capitalization of $1.35 trillion, a P/E ratio of 46.45, a PEG ratio of 1.71 and a beta of 0.40. The stock has a 50-day simple moving average of $1,247.93 and a 200-day simple moving average of $1,112.33.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business’s revenue was up 38.6% on a year-over-year basis. During the same period in the prior year, the firm earned $7.02 EPS. Equities research analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Further Reading

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.